Novostia Technology for Heart Valve Prosthesis Raises CHF 6.5 Million to Start First Clinical Trials

Rapid Unit Sales of Medical Masks to Account for Incremental Revenues in the Global Market Through the COVID-19 Crisis Period

Medical facilities are highly dependent on the use of medical masks during surgeries. The availability of different versions of mask for different applications across different end-users, such as ambulatory surgical centre’s, hospitals, dental settings, etc., are expected to fuel the growth of the medical mask market throughout the forecast period.

Proximie Raises $38m Series B Funding To Accelerate Its Expansion in U.S. and European Markets

F-Prime Capital led financing, joined by Questa Capital, Eight Roads, and Maverick Ventures

RhoVac Reports to Mount Sinai Hospital in New York Join Phase IIb Study in Prostate Cancer

The participation of Mount Sinai was directly caused by the FDA approval of RhoVac's Fast Track Designation.

February 22, 2019

Novostia announces that it raised CHF 6.5 million from private investors to advance its disruptive aortic and mitral heart valve to clinical trials.

Heart valve diseases affect more than 100 million people worldwide. Every year hundreds of thousands of patients undergo a heart valve replacement. Available technologies entail serious constraints: lifelong anticoagulant medication or further replacements due to limited valve durability.

Thanks to a unique patented design and the use of a high-performance biocompatible polymer, Novostia eliminates all these constraints as well as clicking noises.

“Our technology should significantly improve the quality of life of people bearing a heart valve prosthesis, especially kids and young patients, while reducing overall healthcare costs. We appreciate the trust and support of our investors and look forward to bringing this long-awaited innovation to the patients and the physicians,” said Geoffroy Lapeyre, Novostia CEO.

spot_img

DON'T MISS

Related Articles